Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2024-03-28 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Resignation
Regulatory Filings
2024-03-28 English
We wish to inform you that Mr. Marc-Antoine Lucchini (DIN: 08812302), Non-Executive Director, has vide his letter dated 28th March 2024, resigned from the Board of Directors of the Company, ....
Regulatory Filings
2024-03-28 English
The Trading Window of the Company shall remain closed from 1st April 2024, till 48 hours after the announcement of the Financial Results of the Company for the quarter ended 31st March ....
Regulatory Filings Classification · 95% confidence The document is a short notice dated 28th March 2024 from Sanofi India Limited addressed to stock exchanges regarding the closure of the trading window for insiders. It mentions the upcoming declaration of standalone and consolidated financial results for the quarter ended 31st March 2024 and states the trading window will be closed from 1st April 2024 until 48 hours after the announcement of results. The document does not contain any financial data, results, or detailed report content. It is an announcement related to insider trading restrictions ahead of a financial results announcement. The document length is only 1480 characters, indicating it is a brief notice rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-03-28 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice from Sanofi India Limited informing stock exchanges about the closure of the trading window for insiders ahead of the announcement of the quarterly financial results for the quarter ended 31st March 2024. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to compliance and insider trading regulations. The document length is only 1480 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-03-28 English
Please find enclosed a Press Release as regards to an exclusive distribution and promotion agreement between Sanofi India Limited (SIL) and Cipla Limited for distribution and promotion ....
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive distribution and promotion agreement between Sanofi India Limited and Cipla Limited. It is addressed to stock exchanges as a disclosure under Regulation 30 of SEBI (LODR) Regulations, which pertains to material events or information. The content focuses on the business partnership and does not contain financial statements, detailed financial analysis, or regulatory certifications. It is not an annual report, earnings release, or management discussion. The document is a regulatory announcement about a material event affecting the company, fitting the category of Regulatory Filings (RNS).
2024-03-26 English
Please find enclosed a Press Release as regards to an exclusive distribution and promotion agreement between Sanofi India Limited (SIL) and Cipla Limited for distribution and promotion ....
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new exclusive distribution and promotion agreement between Sanofi India Limited and Cipla Limited. It is addressed to stock exchanges as a disclosure under Regulation 30 of SEBI (LODR) Regulations, which pertains to material events or information. The content focuses on the business partnership and does not contain financial statements, earnings data, or detailed financial analysis. It is not a report, transcript, or regulatory filing of financial results or governance changes. The document is a corporate announcement about a business agreement disclosed to the market, fitting the category of Capital/Financing Update (CAP) as it relates to a significant business arrangement impacting the company's operations and potentially its capital structure or market position.
2024-03-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.